

CERTIFICATE OF EFS FILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, via the EFS pursuant to 37 CFR §1.8 on the below date:

Date: April 28, 2008 Name: Sheryl L. Hutchings Signature: *Sheryl L. Hutchings*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Brian L. Bates, et al.

Appln. No.: 10/618,977

Filed: July 14, 2003

For: COATED MEDICAL DEVICE

Attorney Docket No: 8627/742 (PA-5335-RFB)

Examiner: Sweet, Thomas

Art Unit: 3738

Confirmation No.: 5904

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicant hereby cites the following reference:

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Charles, Roger et al., "Ceramide-Coated Balloon Catheters Limit Neointimal Hyperplasia After Stretch Injury in Carotid Arteries", Circ. Res. 2000; 87; 282-288, American Heart Association, Dallas, TX.

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). Applicant respectfully requests the Examiner's consideration of the reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

Pursuant to 37 CFR § 1.97(d), this Third Supplemental Information Disclosure Statement is being filed after the mailing date of a final action under 37 CFR § 1.97(d)(1)(e) and before the payment of the issue fee. Applicant states that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the information disclosure statement.

Applicant has calculated a fee of \$180.00 to be due upon filing this Statement. Therefore, the Director is authorized to charge the calculated fee associated with the filing of this Statement to deposit account 23-1925, as authorized in the accompanying Transmittal.

Respectfully submitted,

4/28/2008
Date

Nicholas M. Boivin
Nicholas M. Boivin (Reg. No.45,650)